Evidence map›Paper›PMID 35041799›Full record

ArticleHuman vaccines & immunotherapeutics2021

"When did you decide to receive the Covid-19 vaccine?" Survey in a high-volume vaccination center.

Marion Le Maréchal, Amina Batel, Stéphanie Bouvier, Hajer Mahdhaoui, Morgane Margotton, Jean-Philippe Vittoz, Etienne Brudieu, Christine Chevallier, Pierrick Bedouch, Saber Touati and 1 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marion Le MaréchalService des maladies infectieuses, Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.
Amina BatelGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Stéphanie BouvierGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Hajer MahdhaouiGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Morgane MargottonGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Jean-Philippe VittozGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Etienne BrudieuDépartement de Pharmacie, Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.
Christine ChevallierDépartement de Pharmacie, Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.
Pierrick BedouchDépartement de Pharmacie, Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.
Saber TouatiGroupe de recherche en infectiologie clinique, CIC-1406, Inserm - CHUGA - Université Grenoble-Alpes, Grenoble, France.
Olivier EpaulardService des maladies infectieuses, Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly efficient and safe Covid-19 vaccines are available in Europe in amounts that theoretically allow for a high immune coverage. However, a notable proportion of the population is reluctant toward immunization. We aimed to determine, among people who chose to be vaccinated, when they made the decision and whether they would have preferred an earlier vaccination. A survey was conducted in a high-volume Covid-19 vaccination center in France from 28 May to 9 July 2021 through an anonymous questionnaire. The 2519 participants (54.1% males; median age 39 years) attributed lower efficacy and safety to Covid-19 vaccines than to vaccines in general. When asked when they decided to receive the vaccine, 15.5% and 16.0% answered "less than one month ago" and "less than one week ago," respectively; age <40 and female sex were independently associated with these responses. When asked whether they would have preferred to have been vaccinated earlier, 57.6% answered "definitely no," "rather no," or "neither yes nor no"; female sex (independently from age) was associated with these answers. When asked whether they would have preferred to receive the vaccine as early as January 2021, 65.2% answered "definitely no," "rather no," or "neither yes nor no"; age <40 and female sex were independently associated with these responses. In conclusion, one-third people had made the decision to be vaccinated only recently, while more than half would not have preferred an earlier vaccination, in particular women and those aged <40 years. Vaccine campaigns should take such short-term decision-making processes into account.

Indexed as

COVID-19COVID-19 VaccinesAdultFemaleHumansMaleSARS-CoV-2Surveys and QuestionnairesVaccinationCOVID-19 VaccinesCovid-19decision-making processvaccine hesitancyvaccine perceptionvaccines

Identifiers

PMID35041799
PMCPMC8903941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.